159 related articles for article (PubMed ID: 9299938)
21. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
[TBL] [Abstract][Full Text] [Related]
22. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
Veltri RW; Miller MC
Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
[TBL] [Abstract][Full Text] [Related]
23. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
Tanaka M; Murakami S; Igarashi T; Abe T; Suzuki K; Sekita N; Shimazaki J
Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
[TBL] [Abstract][Full Text] [Related]
24. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
25. Current usefulness of free/total PSA ratio in the diagnosis of prostate cancer at an early stage.
Pfister C; Basuyau JP;
World J Urol; 2005 Sep; 23(4):236-42. PubMed ID: 16096832
[TBL] [Abstract][Full Text] [Related]
26. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
27. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Steuber T; Nurmikko P; Haese A; Pettersson K; Graefen M; Hammerer P; Huland H; Lilja H
J Urol; 2002 Nov; 168(5):1917-22. PubMed ID: 12394676
[TBL] [Abstract][Full Text] [Related]
28. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
[TBL] [Abstract][Full Text] [Related]
29. [Usefulness of the percentage of free prostatic specific antigen in the differential diagnosis between benign prostatic hyperplasia and prostate cancer].
Gaspar MJ; Arribas I; Hontoria JM; Bokobo P; Coca C; Angulo JC
Med Clin (Barc); 2000 Sep; 115(9):332-6. PubMed ID: 11093893
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios.
Wymenga LF; Duisterwinkel FJ; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ
Scand J Urol Nephrol; 2000 Jun; 34(3):181-7. PubMed ID: 10961472
[TBL] [Abstract][Full Text] [Related]
31. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
32. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
34. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
36. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
[TBL] [Abstract][Full Text] [Related]
37. Critical aspects related to the interpretation of the free-to-total PSA-ratio.
Wolff JM; Stocker G; Borchers H; Haubeck H; Greiling H; Jakse G
Anticancer Res; 1999; 19(4A):2633-6. PubMed ID: 10470208
[TBL] [Abstract][Full Text] [Related]
38. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions.
Gion M; Mione R; Barioli P; Barichello M; Zattoni F; Prayer-Galetti T; Plebani M; Aimo G; Terrone C; Manferrari F; Madeddu G; Caberlotto L; Fandella A; Pianon C; Vianello L
Clin Chem; 1998 Dec; 44(12):2462-70. PubMed ID: 9836713
[TBL] [Abstract][Full Text] [Related]
39. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
40. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
